|drug1504||Hospitalized Patients for COVID-19 Infection Wiki||0.38|
|drug309||Aspirin 81 mg Wiki||0.38|
|drug628||COVID-19 Androgen Sensitivity Test (CoVAST) Wiki||0.38|
|drug986||Daily Vitamin D3 Wiki||0.38|
|drug534||Bolus vitamin D3 Wiki||0.38|
|drug533||Bolus placebo Wiki||0.38|
|drug987||Daily placebo Wiki||0.38|
|drug3677||Vitamin D 1000 IU Wiki||0.38|
|drug3111||Serum zinc, vitamin d vitamin b12 levels . Wiki||0.38|
|drug2669||Prone positioning Wiki||0.22|
|drug3678||Vitamin D3 Wiki||0.15|
|drug3676||Vitamin D Wiki||0.13|
|D014808||Vitamin D Deficiency NIH||0.94|
|D058345||Asymptomatic Infections NIH||0.27|
|D004211||Disseminated Intravascular Coagulation NIH||0.19|
There are 7 clinical trials
Although the novel SARS-CoV-2 virus (COVD-19) is classified as an acute respiratory infection, emerging data show that morbidity and mortality are driven by disseminated intravascular coagulopathy. Untreated CAC leads to microangiopathic thromboses, causing multiple systems organ failure and consuming enormous healthcare resources. Identifying strategies to prevent CAC are therefore crucial to reducing COVID-19 hospitalization rates. The pathogenesis of CAC is unknown, but there are major overlaps between severe COVID-19 and vitamin D insufficiency (VDI). We hypothesize that VDI is a major underlying contributor to CAC. Preliminary data from severe COVID-19 patients in New Orleans support this hypothesis. The purpose of the proposed multi-center, prospective, randomized controlled trial is to test the hypothesis that low-risk, early treatment with aspirin and vitamin D in COVID-19 can mitigate the prothrombotic state and reduce hospitalization rates.
Description: Hospitalization for COVID-19 symptomsMeasure: Hospitalization Time: 2 weeks
The 2019 novel coronavirus disease (COVID-2019) pandemic is an enormous health issue of worldwide scale. Prevention and/or treatment with a widely-available and already-licensed product such as vitamin D (cholecalciferol) could have a large impact on healthcare worldwide. Given ethnic variation in vitamin D production, this could help to address the discrepancies in how people of different ethnicities are affected by COVID-19. There are currently no published studies analysing either individual-level evidence on the effect of vitamin D status on COVID-19 outcomes, or any prospective studies planning on following-up patients with reference to vitamin D and COVID-19 infection. The study will have 2 arms. Arm 1 will recruit patients hospitalised with COVID-19. Vitamin D levels will be measured in these patients and compared with outcome measures of COVID-19 severity. In Arm 2, patients will be recruited prospectively from local general practices (GPs) with measurement of vitamin D levels at enrolment. They will be followed up after 6 months to determine whether baseline vitamin D levels correspond with developing COVID-19. Data will be collected from a mixture of patient medical records, electronic patient records, laboratory data and from patients themselves. Data in Arm 1 will be analysed with a combination of linear and logistic regression, as appropriate, and with adjustment for covariates. Data in Arm 2 will be analysed as a case-control study, with adjustment for covariates. The primary objectives are to determine whether vitamin D levels affect outcomes in COVID-19 infection and whether vitamin D deficiency is associated with increased risk.
Description: Development of COVID-19 during case-control studyMeasure: COVID-19 infection Time: 1 year
Description: Whether hospitalised COVID-19 patients require oxygen therapyMeasure: Oxygen therapy for COVID-19 Time: 1 year
Description: Whether patients hospitalised with COVID-19 were dischargedMeasure: Discharge following COVID-19 hospitalisation Time: 1 year
Description: Whether patients hospitalised with COVID-19 died in hospitalMeasure: Death due to COVID-19 Time: 1 year
In this prospective observational study we aim to study the association of vitamin D deficiency with adverse clinical outcomes in patients infected with Coronavirus disease 2019
Description: death, admission to the intensive care unit, and/or a need for higher oxygen flow than that provided by nasal cannulaMeasure: severe COVID-19 Time: 17/04/2020 to 01/06/2020
This study will measure vitamin D levels in adults with COVID 19. Participants with low levels of vitamin D will be entered into an open label trial of supplementation with vitamin D.
Description: change in level of Vitamin D, 25-Hydroxy between the two time pointsMeasure: Vitamin D levels Time: baseline and after two weeks of vitamin D supplementation
Description: We will calculate the change in severity of COVID 19 symptoms from baseline to 2 weeks after vitamin D supplementationMeasure: severity of COVID 19 symptoms Time: baseline and at 2 weeks after vitamin D supplementation
Zinc d vitamin and b12 serum levels in covid-19 positive pregnants will be compared in terms of patients' responses to computed tomography and treatment.
Description: Serum zinc, vitamin d vitamin b12 levels of 45 patients will be measured and evaluated together with the information of the patients.Measure: Serum zinc, vitamin d vitamin b12 deficiency levels Time: 2 months
This study is intended to address whether oral daily vitamin D supplementation reduces infection with SARS-CoV-2 in healthy young adults. The primary aim of the study is to demonstrate a reduction in 'silent' seroconversion rates, consistent with asymptomatic transmission of SARS-CoV-2, in a young healthy adult population following 24 weeks of taking oral vitamin D supplemented at a dose of 1000 I.U. daily, versus matching placebo. The secondary aims of this study are to explore: 1. Any effect on symptomatic illness. 2. The background 'point' prevalence and subsequent rate of increase in seropositivity for SARS-CoV-2 in healthy young adults. 3. The individual reductions in seropositivity to SARS-CoV-2 over time, and changes in seropositivity in a defined young adult population over time. 4. Where salivary Immunoglobulin A (IgA) may be used to provide an alternative/ complementary serological method 5. The effect (if any) of vitamin D supplementation on seroconversion rates stratified by: i) level of baseline vitamin D 'deficiency/ insufficiency/ sufficiency' status; ii) extent of BMI-defined normal/overweight/obesity cut-offs and iii) gender.
Description: asymptomatic seroconversion for SARS-CoV-2Measure: Seroconversion Time: 24 weeks
Description: asymptomatic seroconversion for SARS-CoV-2Measure: Interim analysis - seropositivity at 12 weeks Time: 12 weeks
Description: Sensitivity and specificity of dried blood spot assay compared with venous blood serologyMeasure: Dried Blood Spot performance Time: 24 weeks
Description: Sensitivity and specificity of salivary IgA compared with venous blood serologyMeasure: Salivary IgA performance Time: 24 weeks
Description: The background 'point' prevalence and subsequent rate of increase in seropositivity for SARS-CoV-2 in healthy young adults.Measure: Prevalence of SARS-CoV-2 Time: 24 weeks
Description: The individual reductions in seropositivity to SARS-CoV-2 over time, and changes in seropositivity in a defined young adult population over timeMeasure: Change in seropositivity Time: 24 weeks
Description: The effect of vitamin D supplementation on seroconversion rates stratified by: i) level of baseline vitamin D 'deficiency/ insufficiency/ sufficiency' status; ii) extent of BMI-defined normal/overweight/obesity cut-offs, iii) gender iv) ethnicityMeasure: Change in seroconversion rate Time: 24 weeks
The purpose of this study is to evaluate how useful vitamin D supplementation is in reducing the severity of COVID-19 symptoms and the body's inflammatory and infection-fighting response to COVID-19. Individuals ≥50 years of age and older who are tested for COVID-19 and negative will be randomized (like flipping a coin) to either daily high dose vitamin D supplementation (6000 IU vitamin D3/day) vs. standard of care. Those individuals ≥50 years of age or older who test positive for COVID-19 at baseline will be randomized to bolus vitamin D (20,000 IU/day for 3 days) followed by high dose (6000 IU vitamin D/day) vs. standard of care for 12 months. All participants will receive a multivitamin containing vitamin D.
Description: metabolite of vitamin DMeasure: Change in total circulating 25(OH)D concentration Time: monthly in COVID-19 negative participants through study completion for 1 year
Description: metabolite of vitamin DMeasure: Change in total circulating 25(OH)D concentration in COVID-19 positives Time: baseline, 2 and 4 weeks, then months 3, 6, 9 and 12 in COVID-19 positive participants
Description: The presence or absent of SARS-CoV-2 antibody will be measured at baseline, 3, 6, 9 and 12 months.Measure: Change in SARS-CoV-2 antibody titers Time: every 3 months up to 12 months
Description: At baseline, 3, 6, 9 and 12 months, inflammatory cytokines will be measured in participant plasma samples. Cytokines to be measured are Interferon-gamma (IFN-g), Interleukin-1beta (IL-1B), IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-13, and Tumor Necrosis Factor-alpha (TNFa). Values of these cytokines at baseline will compared to those at 3, 6, 9, and 12 monthsMeasure: Change in inflammatory cytokine concentration (10 cytokine panel Elisa: Interferon (INF)-gamma, Interleukin (IL)-1beta, IL-2, IL-3, IL-4, IL-6, IL-8, IL-10, IL-13, Tumor Necrosis Factor (TNF)-alpha Time: baseline and every 3 months up to 12 months
Description: COVID-19 positive participants or if COVID-19 negatives develop respiratory symptoms will complete this respiratory survey daily for 2 weeksMeasure: Respiratory symptoms Time: daily for 2 weeks
Description: Inventory of signs and symptoms of rhino/sinusitis. These signs include sneezing, running nose, cough, dizziness, fatigue, and sense of smell. Each sign is rated on a scale of 0 to 5, with 0 indicating not problem, for instance 1 indicating mild problem, 4 indicating severe problem and 5 indicating problem as bad as it can be.Measure: Signs and symptoms of rhino/sinusitis Time: Baseline then 3, 6, 9 and 12 months in negatives and daily for 2 weeks in positives
Description: Dietary intake assessmentMeasure: NCI Dietary Intake Time: baseline then at 6 and 12 months
Description: Survey of participant health problemsMeasure: Charlson Comorbidity survey Time: baseline then at 6 and 12 months
Description: Assessment of physical activity of each participantMeasure: Paffenberger Physical Activity Assessment Time: Baseline then at 6 and 12 months
Description: Each participant will complete the Perceived Stress Scale Questionnaire (PSS) to assess their perceived stress. Assessments are base on a scale of 0 to 4, with 0 indicating "never" and 4 indicating "very often"Measure: Perceived stress Time: monthly for 1 year
Description: Each participant will complete the and Pandemic Stress Index Questionnaire (PSI) to assess their perceived stress cause by the pandemic. Assessments are base on a scale of 0 to 6, with 0 indicating "not at all" and 5 indicating "extremely," and 6 indicating "decline to answer."Measure: Pandemic stress Time: monthly for 1 year
Description: Personality characteristics of each participantMeasure: NEO-Personality Inventory Time: baseline visit
Description: A health assessment will be completed by each participant monthly for 1year. This health. This is for information on health status only and not for comparative assessment.Measure: GrassrootsHealth Monthly Health assessment Time: baseline, 6, and 12 months
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports